Metropolitan Life Insurance Co NY reduced its stake in shares of Balchem Co. (NASDAQ:BCPC – Get Rating) by 75.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,011 shares of the basic materials company's stock after selling 6,209 shares during the quarter. Metropolitan Life Insurance Co NY's holdings in Balchem were worth $275,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of BCPC. Intelligent Financial Strategies acquired a new position in Balchem during the 4th quarter valued at about $25,000. UMB Bank N A MO bought a new position in shares of Balchem in the fourth quarter valued at approximately $56,000. Carolinas Wealth Consulting LLC increased its stake in shares of Balchem by 130.5% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 484 shares of the basic materials company's stock valued at $82,000 after acquiring an additional 274 shares during the period. First Horizon Advisors Inc. raised its holdings in Balchem by 43.1% during the fourth quarter. First Horizon Advisors Inc. now owns 558 shares of the basic materials company's stock worth $93,000 after purchasing an additional 168 shares in the last quarter. Finally, Destiny Wealth Partners LLC boosted its stake in Balchem by 58.4% during the 1st quarter. Destiny Wealth Partners LLC now owns 659 shares of the basic materials company's stock valued at $90,000 after purchasing an additional 243 shares in the last quarter. Institutional investors and hedge funds own 89.15% of the company's stock.
Get Balchem alerts:Balchem Stock Up 3.1 %
Shares of Balchem stock opened at $134.35 on Thursday. Balchem Co. has a 12-month low of $110.15 and a 12-month high of $174.29. The firm has a market capitalization of $4.32 billion, a PE ratio of 40.22 and a beta of 0.59. The company has a quick ratio of 1.64, a current ratio of 2.62 and a debt-to-equity ratio of 0.50. The stock's fifty day moving average is $131.75 and its 200-day moving average is $129.99.
Insider Buying and Selling
In other Balchem news, VP Gunsteren Job Leonard Van sold 3,601 shares of the company's stock in a transaction dated Wednesday, August 3rd. The shares were sold at an average price of $125.62, for a total transaction of $452,357.62. Following the completion of the sale, the vice president now directly owns 1,430 shares of the company's stock, valued at $179,636.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is currently owned by company insiders.Wall Street Analysts Forecast Growth
Several analysts have recently weighed in on BCPC shares. HC Wainwright upped their price objective on Balchem from $152.00 to $164.00 and gave the company a "buy" rating in a report on Monday, August 22nd. StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a research report on Monday, August 1st.
Balchem Profile
(Get Rating)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
See Also
- Get a free copy of the StockNews.com research report on Balchem (BCPC)
- 3 High Margin Chipmakers Bound to Recover
- 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Get Rating).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.